Beyondspring Inc (BYSI) - News Archive

The treatment landscape for metastatic non-small cell lung cancer (NSCLC) has significantly evolved with the advent of immune checkpoint inhibitors (ICIs). Despite initial efficacy, resistance often follows treatment, n...

Revolutionizing NSCLC Treatment: Plinabulin/Docetaxel Combination Offers Enhanced Survival and Quality of LifeAt the forefront of oncological research, BeyondSpring Pharmaceuticals has unveiled promising final data from...

BeyondSpring Inc. recently delivered a significant oral presentation at the ISLAC 2024 World Conference on Lung Cancer, highlighting the final Phase 3 data for its lead anti-cancer asset, Plinabulin, in the context of s...

In a significant advancement in the realm of drug discovery, SEED Therapeutics, a pioneering biotechnology company, has announced a strategic research collaboration with Eisai Co., Ltd. This collaboration is aimed at di...

BeyondSpring Inc., a clinical-stage global biopharmaceutical company specializing in innovative cancer therapies, recently held a virtual Research and Development (R&D) Day to highlight its latest breakthroughs. The eve...

BeyondSpring Inc., a global biopharmaceutical company focused on developing innovative cancer therapies, announced today that the first patient has been dosed in a Phase 2 investigator-initiated trial with Pembrolizumab...

BeyondSpring Inc., a global clinical-stage biopharmaceutical company, recently announced that it received a Foreign Delinquency Compliance Plan Alert Letter from The Nasdaq Stock Market LLC. This letter notified the com...